$2.04
0.00%
Nasdaq, Aug 30, 12:59 am CET
ISIN
US23284F1057
Symbol
CTMX

CytomX Therapeutics, Inc. Stock price

$2.04
-0.21 9.33% 1M
+1.36 201.24% 6M
+1.01 98.06% YTD
+0.89 77.39% 1Y
+0.55 36.91% 3Y
-5.26 72.05% 5Y
-10.86 84.19% 10Y
-10.86 84.19% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.01 0.49%
ISIN
US23284F1057
Symbol
CTMX
Industry

Key metrics

Basic
Market capitalization
$336.4m
Enterprise Value
$178.3m
Net debt
positive
Cash
$158.1m
Shares outstanding
164.9m
Valuation (TTM | estimate)
P/E
5.5 | 116.3
P/S
2.4 | 3.5
EV/Sales
1.3 | 1.9
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
-0.4%
Return on Equity
-6,988.8%
ROCE
31.8%
ROIC
-784.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$141.1m | $95.8m
EBITDA
$44.7m | $6.1m
EBIT
$43.1m | $-24.1m
Net Income
$48.0m | $2.9m
Free Cash Flow
$-77.7m
Growth (TTM | estimate)
Revenue
18.0% | -30.6%
EBITDA
486.6% | -77.1%
EBIT
654.1% | -196.6%
Net Income
333.0% | -90.9%
Free Cash Flow
10.0%
Margin (TTM | estimate)
Gross
-
EBITDA
31.7% | 6.4%
EBIT
30.6%
Net
34.0% | 3.0%
Free Cash Flow
-55.1%
More
EPS
$0.4
FCF per Share
$-0.5
Short interest
15.8%
Employees
120
Rev per Employee
$1.2m
Show more

Is CytomX Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

CytomX Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a CytomX Therapeutics, Inc. forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a CytomX Therapeutics, Inc. forecast:

Buy
85%
Hold
15%

Financial data from CytomX Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
141 141
18% 18%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 30 30
4% 4%
21%
- Research and Development Expense 68 68
18% 18%
48%
45 45
487% 487%
32%
- Depreciation and Amortization 1.57 1.57
17% 17%
1%
EBIT (Operating Income) EBIT 43 43
654% 654%
31%
Net Profit 48 48
333% 333%
34%

In millions USD.

Don't miss a Thing! We will send you all news about CytomX Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytomX Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.
Neutral
GlobeNewsWire
20 days ago
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the f...
Neutral
Seeking Alpha
24 days ago
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A.
More CytomX Therapeutics, Inc. News

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Sean McCarthy
Employees 120
Founded 2010
Website cytomx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today